pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

Transcend Therapeutics Inc

updated 3mo ago
Website ↗
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(1)

pipeline depth1 products
Phase 3: 1
1Phase 3
Phase 3
TSND-201
Post-Traumatic Stress Disorder (PTSD)

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase3An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSDrecruitingn=300
  • phase3An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD (EMPOWER-1)recruitingn=300
  • phase3An Evaluation of the Long-Term Safety and Efficacy of TSND-201 for the Treatment of PTSDenrolling by invitationn=300
  • phase2A Study to Assess the Use of Methylone in the Treatment of PTSDcompletedn=79
  • phase2An Evaluation of the Safety and Efficacy of Methylone for the Treatment of PTSDcompletedn=62
  • phase2An Evaluation of the Long-term Efficacy and Safety of Methylone for the Treatment of PTSDcompletedn=44
  • phase1A Single, Ascending Dose Evaluation of the Safety, Pharmacokinetics of Methylone in Healthy Subjectscompletedn=40
🐶 Hiring Signal
No open roles indexed yet — view Transcend Therapeutics Inc jobs →

News

  • ARPA-H bets $4.9 million on ibogaine for PTSD treatment in veterans
    The U.S. department of health and human services announced a $4.9 million bet to advance the development of ibogaine for post-traumatic stress disorder (PTSD).
    fiercebiotech · 5d ago
  • Delix raises $100M to advance at-home psychedelic without hallucinogenic effects
    The series C raise, co-led by Johnson & Johnson’s venture capital arm, will help Delix Therapeutics push its novel psychedelic asset into mid-stage development for major depressive disorder.
    biospace · 7d ago
  • Delix raises $100M to advance at-home psychedelic without hallucinatory effects
    The series C raise, co-led by Johnson & Johnson’s venture capital arm, will help Delix Therapeutics push its novel psychedelic asset into mid-stage development for major depressive disorder.
    biospace · 7d ago
  • Update: Compass submits psilocybin depression drug for approval after stock wobbles
    Compass Pathways has completed an FDA filing for COMP360, with an expected launch in the first half of next year. The update follows a reported regulatory submission for Usona Institute’s own psilo…
    biospace · 8d ago
  • BioSpace 40 Under 40 winners make their mark on biopharma
    40 Under 40 honorees’ accomplishments include co-developing the world’s first synthetic biology programming language for mRNA and co-founding and leading a company acquired for $700 million up-fron…
    biospace · 1mo ago
  • As ‘cultural weight’ of a psychedelic approval looms, FDA hearing focuses on access and safety
    As the FDA marches toward the likely first approval of a psychedelic medicine, the agency today convened a hearing seeking public input on how these drugs should be used, monitored and continuously…
    fiercebiotech · 2mo ago
  • Psychedelic therapies ride wave of public favor into FDA hearing
    Heading into an FDA hearing on Monday regarding the future of psychedelic treatments, public comments show wide support for further exploring the therapeutic potential of these compounds—to match r…
    biospace · 2mo ago
  • Psilocybin proves promising in neuropathic pain mouse study
    Amid the rise of psychedelics in the mental health space, researchers have begun to explore psilocybin as a treatment for chemotherapy-induced peripheral neuropathy.
    fiercebiotech · 2mo ago
  • Psychedelics on the cusp of market breakthrough as clinical, policy support grow
    While there are several FDA-approved psychiatric medicines on the market, many patients still struggle to achieve lasting symptom relief. Psychedelics could help fill this gap.
    biospace · 3mo ago
  • Lilly’s $3.8B psychedelics bet won’t open the M&A floodgates
    Eli Lilly’s $3.8 billion play for AtaiBeckley has fueled speculation that Big Pharma is ready to embrace psychedelics. But while the acquisition does validate the drug class, analysts say it is unl…
    biospace · 3mo ago
view all news mentions →
identifiers
source
globaldata
mentioned in
10news items
entity-linker matched

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?